Short course single daily ceftriaxone monotherapy for acute bacterial meningitis in children: Results of a Swiss multicenter study. Part I: Clinical results

Infection

Volumn 18, Issue 2, 1990, Pages 70-77

  Martin, E ^a   Guggi, T ^a   Hohl, P ^b   Fernex, M ^b   Kayser, F H ^c  

^a Universitats Kinderklinik   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE;

ADOLESCENT; ARTICLE; BACTERIAL MENINGITIS; BACTERIUM ISOLATION; CEREBROSPINAL FLUID; CHILD; CLINICAL FEATURE; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; HAEMOPHILUS INFLUENZAE; HEARING TEST; HUMAN; INFANT; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; RASH; STOMATITIS; STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; BACTERIAL INFECTIONS; CEFTRIAXONE; CEREBROSPINAL FLUID; CHILD; CHILD, PRESCHOOL; FEMALE; HUMAN; INFANT; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; MALE; MENINGITIS; MULTICENTER STUDIES; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; SUPPORT, NON-U.S. GOV'T; SWITZERLAND;

EID: 0025312201     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/BF01641418     Document Type: Article

References (36)

1. Bactericidal and bacteriostatic action of chloramphenicol against meningeal pathogens
2. Listeria and gram-negative bacillary meningitis in New York City, 1972–1979: Frequent causes of meningitis in adults
3. Antibiotic therapy of bacterial meningitis: Lessons we've learned
4. Designing appropriate therapy in the treatment of gram-negative bacillary meningitis
5. Meningitis due to Haemophilus influenzae type b resistant to both ampicillin and chloramphenicol
6. Meningitis due to Haemophilus influenzae type b resistant to ampicillin and chloramphenicol
7. Prolonged pneumococcal meningitis due to an organism with increased resistance to penicillin
8. Multiple resistant pneumococcus causing meningitis: Its epidemiology within a day-care center
9. Susceptibility of pneumococci to 14 beta-lactam agents: Comparison of strains resistant, intermediate resistant, and susceptible to penicillin
10. Ceftriaxone versus ampicillin and chloramphenicol for treatment of bacterial meningitis in children
11. Rationale for clinical trials evaluating ceftriaxone in the therapy of bacterial meningitis
12. Comparison of ceftriaxone with standard therapy for bacterial meningitis
13. Comparaison bactériologique, pharmacologique et clinique de l'amoxycilline et du ceftriaxone dans 300 méningites purulantes
14. Comparison of ceftriaxone and traditional therapy of bacterial meningitis
15. Aminoglycoside therapy of gram-negative bacillary meningitis
16. Past and current roles of cephalosporin antibiotics in treatment of meningitis
17. A comparison of the pharmacokinetics and tissue penetration of ceftriaxone, moxalactam, and cefotaxime
18. Ceftriaxone kinetics and cerebrospinal fluid penetration in infants and children with meningitis
19. Ceftriaxone, a review of its antibacterial activity, pharmacological properties and therapeutic use
20. Pharmacokinetics of Rocephin ®, a highly active new cephalosporin with an exceptionally long biological half-life
21. Pharmacokinetics of ceftriaxone in neonates and infants with meningitis
22. Comparison of the efficacy and safety of ceftriaxone to ampicillin/chloramphenicol in the treatment of childhood meningitis
23. Ceftriaxone for meningitis (letter)
24. Once-daily administration of ceftriaxone in the treatment of meningitis and other serious infections in children
25. Pharmacokinetic profile of ceftriaxone in man
26. Intramuscular ceftraxone versus ampicillin-chloramphenicol in childhood bacterial meningitis
27. Effects of concentration-dependent protein binding on ceftriaxone kinetics
28. Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration dependent protein binding. I. Theoretical considerations
29. Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration dependent protein binding. II. Physiological significance
30. Diffusion of ceftriaxone in the cerebrospinal fluid
31. Safety and efficacy of once daily ceftriaxone for the treatment of bacterial meningitis
32. Prospective comparative trial of ceftriaxone vs. conventional therapy for treatment of bacterial meningitis in children
33. Seven days of ceftriaxone therapy is as effective as ten days' treatment for bacterial meningitis
34. Delayed cerebrospinal fluid sterilization and adverse outcome of bacterial meningitis in infants and children